Effects of dabigatran on coagulation assays in aged patients with atrial fibrillation: Two cases report

Xiaoping Hou, Xuan Wei, Yanyan Li

Air Force General Hospital of PLA

OBJECTIVES To report the effects of dabigatran etexilate on routine coagulation assays in two aged patients with atrial fibrillation.

METHODS The data of routine coagulation assays from two aged cases treated with dabigatran etexilate were retrospectively reviewed.

GW26-e2949 Effects of dabigatran on coagulation assays in aged patients with atrial fibrillation: Two cases report

Xiaoping Hou, Xuan Wei, Yanyan Li

Air Force General Hospital of PLA

OBJECTIVES To report the effects of dabigatran etexilate on routine coagulation assays in two aged patients with atrial fibrillation.

METHODS The data of routine coagulation assays from two aged cases treated with dabigatran etexilate were retrospectively reviewed.

GW26-e1008 Effects of Shensongyangxin capsule on heart rates variability and insomnia in maintenance hemodialysis patients

Zhenda Zheng, Caihong Xu, Xiaoju Ma, Jianrui Zheng, Callian Cheng

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

OBJECTIVES To investigate the efficacy and safety of Shensongyangxin capsule (SSYX) on heart rates variability (HRV) and insomnia in maintenance hemodialysis patients.

METHODS Sixty-three maintenance hemodialysis patients in the third affiliated hospital of Sun Yat-Sen University from 2013 June to December were divided into two groups, SSYX treatment group(n=33) and control group(n=30). SSYX treatment group were received SSYX 4 capsules four times a day for eight weeks, all patients received 24-h holter test and Pittsburgh sleep quality index were measured at both baseline and eight weeks in these sixty-three patients.

RESULTS SSYX can improve heart rate variability [SDNN (93.2±19.1) vs. (82.4±13.1) ms, P<0.05], RMSSD (28.3±11.4) ms vs. (21.8±11.9) ms, P<0.05]. SSYX can decrease the incidence of arrhythmia [premature atrial contraction (60.6% vs.24.2%), atrial tachycardia (45.5% vs.12.1%), premature ventricular contraction (9.1% vs.3.3%), atrial-ventricular block (60.6% vs.24.2%), P<0.05]. SSYX also improved sleep quality significantly[PSQI (6.28±2.12) vs. (4.39±2.94), P<0.05]. There was no severe adverse events registered during the study.

CONCLUSIONS Clinical use of SSYX was safe and effective for treating hemodialysis patients with decrease HRV and insomnia.